Biologics
Ann Allergy Asthma Immunol
.
2018 Apr;120(4):354-356.
doi: 10.1016/j.anai.2018.02.030.
Authors
Chitra Dinakar
1
,
David A Khan
2
,
Stanley M Fineman
3
,
David Michael Lang
4
,
Stephen A Tilles
5
Affiliations
1
AllergyWatch, Sacramento, California; Medicine, Pulmonary & Critical Care Medicine, Stanford University, Stanford, California; Asthma and Immunodeficiency, Stanford Health Care, Stanford, California.
2
AllergyWatch, Sacramento, California; Division of Allergy & Immmunology, University of Texas Southwestern Medical School, Dallas, Texas.
3
AllergyWatch, Sacramento, California; Atlanta Allergy & Asthma, Marietta, Georgia.
4
AllergyWatch, Sacramento, California; Department of Allergy and Clinical Immunology, Respiratory Institute, Cleveland Clinic, Cleveland, Ohio.
5
AllergyWatch, Sacramento, California; Northwest Asthma & Allergy Center, Redmond, Washington. Electronic address: stilles@nwasthma.com.
PMID:
29625663
DOI:
10.1016/j.anai.2018.02.030
No abstract available
Publication types
Research Support, Non-U.S. Gov't
Review
MeSH terms
Asthma / drug therapy*
Biological Products / therapeutic use*
Dermatitis, Atopic / drug therapy*
Humans
Nasal Polyps / drug therapy*
Urticaria / drug therapy*
Substances
Biological Products